Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia

Haematologica

Volumn 85, Issue 7, 2000, Pages 711-721

  Wuchter, C ^a   Karawajew, L ^a   Ruppert, V ^a   Schrappe, M ^a   Buchner, T ^a   Schoch, C ^a   Haferlach, T ^a   Harbott, J ^a   Ratei, R ^a   Dorken, B ^a   Ludwig, W D ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Acute leukemia; Multidrug resistance; P glycoprotein expression and function

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MRK 16; PREDNISONE; RHODAMINE 123;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; GLYCOPROTEIN SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PROGNOSIS; TREATMENT FAILURE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; BONE MARROW CELLS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; MIDDLE AGED; P-GLYCOPROTEIN; PHENOTYPE; PROGNOSIS; RECURRENCE; SURVIVAL RATE;

EID: 0033867660     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Clinical significance of CD95, Bcl-2 and Bax expression in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics
2. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients
3. Cytogenetics and P-glycoprotei n (PG P) are independent predictors of treatment outcome in acute myeloid leukemia (AML)
4. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay
5. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis
6. Relationship between MDR1 gene and surface markers in acute myeloid leukemia
7. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia
8. P-glycoprotein expression and prognostic value in acute myeloid leukemia
9. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells pred ct a poor response to chemotherapy and reduced patient survival
10. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia
11. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: Results of a 6-year prospective study
12. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: Prognostic implications
13. The expression of the multidrug resistance related glycoprotein in adult acute lymphoblastic leukemia
14. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia
15. Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: A report from the Children's Cancer Group
16. Expression of the multidrug resistance P glycoprotein in newly diagnosed adult acute lymphoblastic leukemia: Absence of correlation with response to treatment
17. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations
18. Phenotypic and genotypic analyses of multidrug resistance (MDR) in clinical hospital practice
19. Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins
20. Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine. A randomized trial by the German AML cooperative group
21. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86
22. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
23. Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: The significance of initial therapy response in blood and bone marrow
24. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group
25. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group
26. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)
27. Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody
28. Clinical significance of surface antigen expression in children with acute myeloid leukemia: Results of study AML-BFM-87
29. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trials GMALL 03/87 and 04/89
30. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leu kemias (EGIL)
31. Functional role for the 170-to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monocional antibodies
32. Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein
33. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody
34. Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein
35. Expression and functional activity of P-glycoprotein in adult acute myelogenous leukemia patients
36. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia
37. Low Frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia
38. ISCN 1995, Guidelines for Cancer Cytogenetics. Supplement to: An International System for Human Cytogenetic Nomenclature
39. Functional expression of MDR-1 in acute myeloid leukemia: Correlation with the clinical-biological, immunophenotypical, and prognostic disease characteristics
40. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study
41. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells
42. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype
43. Developmentally regulated expression of P-glycoprotein (multidrug resistance) activity in mouse thymocytes
44. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and inteferon-gamma in normal human T lymphocytes
45. Extrusion of the P glycoprotein substrate rhodamine-123 distinguishes CD4 memory T cell subsets that differ in IL-2-driven IL-4 production
46. Multiple drug resistance mediated by P-glycoprotein is not a major factor in a slow response to therapy in childhood ALL
47. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells
48. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies
49. Multicentric evaluation of the MDR phenotype in leukemia. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hopitaux de Paris
50. Theoretical and practical considerations for the measurement of P-glycoprotein Function in acute myeloid leukemia
51. Optimal immunocyrochemical and flow cyrometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia
52. Frequency and clinical significance ofthe expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study
53. Correlation of P-glycoprotein expression and Function in childhood acute leukemia: A Children's Cancer Group study
54. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/efflux+ and MDR1+/efflux-cases
55. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia
56. Phosphorylation site mutations in the human multidrug transporter modulate its drug-stimulated ATPase activity
57. The detection of rhodamine 123 efflux at low levels of drug resistance
58. Preclinical investigations of drug resistance
59. Resistance to chemotherapy in acute leukemia
60. Multidrug resistance in leukaemia
61. The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance
62. Quality control of multidrug resistance assays in adult acute leukemia: Correlation between assays for P-glycoprorein expression and activity